TuisMOLN • NASDAQ
add
Molecular Partners AG
Vorige sluiting
$3,75
Dagwisseling
$3,72 - $3,74
Jaarwisseling
$3,36 - $7,60
Markkapitalisasie
144,10 m USD
Gemiddelde volume
3,66 k
P/V-verhouding
-
Dividend-opbrengs
-
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CHF) | Jun. 2025info | J/J-verandering |
|---|---|---|
Inkomste | — | — |
Bedryfskoste | 3,99 m | -10,05% |
Netto inkomste | -20,40 m | -35,25% |
Netto winsgrens | — | — |
Wins per aandeel | -0,56 | — |
EBITDA | -14,15 m | 7,98% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CHF) | Jun. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 114,49 m | -28,05% |
Totale bates | 124,25 m | -27,17% |
Totale aanspreeklikheid | 17,59 m | 16,89% |
Totale ekwiteit | 106,66 m | — |
Uitstaande aandele | 37,39 m | — |
Prys om te bespreek | 1,32 | — |
Opbrengs op bates | -27,70% | — |
Opbrengs op kapitaal | -30,77% | — |
Kontantvloei
Netto kontantverandering
| (CHF) | Jun. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -20,40 m | -35,25% |
Kontant van bedrywe | -13,10 m | 16,68% |
Kontant van beleggings | 14,97 m | 13,85% |
Kontant van finansiering | -243,00 k | 8,99% |
Netto kontantverandering | 603,00 k | 122,68% |
Beskikbare kontantvloei | -3,61 m | 63,16% |
Meer oor
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Gestig
2004
Webwerf
Werknemers
153
